CORRECTING and REPLACING NanoSphere Closes $2 Million Private Placement Offering
February 21, 2019
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO
U.S. WIRE SERVICES
DENVER–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NSHS&src=ctag” target=”_blank”gt;$NSHSlt;/agt;–Please replace the release issued February 21, 2019 with the following
corrected version due to multiple revisions.
The corrected release reads:
NANOSPHERE CLOSES $2 MILLION PRIVATE PLACEMENT OFFERING
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO
U.S. WIRE SERVICES
NanoSphere
Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“Nanosphere” or “the
Company”) is pleased to announce that it has closed its non-brokered
private placement announced on Feb. 11, 2019 issuing 6,666,394 units at
a price of 30 cents per unit for gross proceeds of $1,999,918.20.
Each unit is comprised of one common share and a full purchase warrant
exercisable to purchase a further common share at a price of 50 cents
for a period of 24 months, subject to accelerated expiry if the
Company’s shares trade at or above 75 cents for 15 consecutive days. In
connection with the closing, the company paid an aggregate of $41,931.41
in finders’ fees and issued 106,050 finders’ warrants having the same
terms as the private placement warrants. All securities issued are
subject to a statutory hold period expiring June 22, 2019.
Including the tranche closed in December 2018, the Company has issued an
aggregate of 11,118,648 units for aggregate gross proceeds of
$3,335,594. The proceeds will be used to expand the Company’s
award-winning Evolve Formulatm cannabis products into new
markets in the US, Canada and Mexico, further product development and
marketing, shareholder communications and general working capital.
About NanoSphere
NanoSphere Health Sciences LLC, is a biotechnology firm specializing in
the creation of the NanoSphere Delivery System™, a revolutionary
platform using nanotechnology in the biodelivery of supplements,
nutraceuticals and over-the-counter medications for the cannabis,
pharmaceutical and animal health industries. For more information on
NanoSphere, please visit http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world’s first and only
scientifically proven nanoparticle delivery system in cannabis. Evolve’s
pioneering product, Transdermal NanoSerum™, is a fast-acting,
ultra-strength transdermal formula infused with nano-encapsulated
cannabis and cannabis extracts. For more information on Evolve Formulas,
visit
https://www.evolveformulas.com/. Follow us on
Facebook,
Instagram and
Twitter.
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this news
release which are not purely historical are forward looking statements,
including without limitation any statements concerning the Company’s
intentions, plans, estimates, expectations or beliefs regarding the
future. Although the Company believes that any forward looking
statements in this news release are reasonable, there can be no
assurance that any such forward looking statements will prove to be
accurate. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Without limitation, these include assumptions, risks and uncertainties
inherent in completing sub-licensing arrangements in the United States,
Canada and abroad, product demand, production, competition and
government regulation of the Cannabis industry, any and all of which may
have an adverse effect on the Company’s expansion plans, sales, revenues
and its financial results and condition. Readers are advised to
rely on their own evaluation of such risks and uncertainties and should
not place undue reliance on forward looking statements. Any forward
looking statements are made as of the date of this news release, and the
Company assumes no obligation to update the forward looking statements,
or to update the reasons why actual events or results could or do differ
from those projected in the forward looking statements, whether as a
result of new information, future events or otherwise.
Contacts
On behalf of the Board
Robert Sutton, Chairman and CEO
Direct:
(720) 845-1465
Investor Contact:
Victor
Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail:
vgoncalves@nanospherehealth.com